Edwards Lifesciences Corporation (EW) reported Q1 2026 results with total revenues of $1.65 billion, up 16.7% year-over-year and slightly above the revenue estimate of $1.64 billion. Diluted earnings per share came in at $0.66, an 8.2% increase year-over-year but below the EPS estimate of $0.75.
Key income statement highlights:
Cash flow and balance sheet snapshot:
Cost and margin note: cost of sales rose to $362.6 million, up 20.2% year-over-year, while gross profit increased to $1.29 billion, supporting improved operating profitability.
Market reaction: shares moved by 3.17% since market close following the release.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Edwards Lifesciences Corporation Insider Trading Activity
Edwards Lifesciences Corporation insiders have traded $EW stock on the open market 28 times in the past 6 months. Of those trades, 0 have been purchases and 28 have been sales.
Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:
- DONALD E JR BOBO (CVP,Strategy/Corp Development) has made 0 purchases and 9 sales selling 92,086 shares for an estimated $7,680,319.
- SCOTT B. ULLEM (CVP, Chief Financial Officer) has made 0 purchases and 7 sales selling 46,700 shares for an estimated $3,874,945.
- BERNARD J ZOVIGHIAN (CEO) has made 0 purchases and 4 sales selling 47,780 shares for an estimated $3,873,114.
- DANIEL J. LIPPIS (CVP, TAVR) has made 0 purchases and 5 sales selling 5,096 shares for an estimated $426,680.
- HEISZ LESLIE STONE sold 2,615 shares for an estimated $218,119
- DAVEEN CHOPRA (CVP, TMTT & Surgical) sold 2,000 shares for an estimated $168,750
- WAYNE MARKOWITZ (CVP, JAPAC) sold 583 shares for an estimated $50,143
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Edwards Lifesciences Corporation Hedge Fund Activity
We have seen 527 institutional investors add shares of Edwards Lifesciences Corporation stock to their portfolio, and 580 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 16,954,947 shares (-75.9%) from their portfolio in Q4 2025, for an estimated $1,445,409,231
- MILLENNIUM MANAGEMENT LLC added 4,301,241 shares (+241.7%) to their portfolio in Q4 2025, for an estimated $366,680,795
- VIKING GLOBAL INVESTORS LP removed 3,069,151 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $261,645,122
- HOLOCENE ADVISORS, LP removed 2,495,651 shares (-52.6%) from their portfolio in Q4 2025, for an estimated $212,754,247
- MARSHALL WACE, LLP added 2,359,128 shares (+66.1%) to their portfolio in Q4 2025, for an estimated $201,115,662
- CITADEL ADVISORS LLC removed 2,030,643 shares (-48.0%) from their portfolio in Q4 2025, for an estimated $173,112,315
- FMR LLC added 2,003,735 shares (+13.7%) to their portfolio in Q4 2025, for an estimated $170,818,408
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Edwards Lifesciences Corporation Government Contracts
We have seen $28,352,410 of award payments to $EW over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- EXPRESS REPORT: HEART VALVES: $295,500
- HTM EV1000 PATIENT MONITORS: $246,000
- HEART VALVE: $238,000
- TRANSCATHETER HEART VALVE REPLACEMENT SYSTEMS: $238,000
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Edwards Lifesciences Corporation Congressional Stock Trading
Members of Congress have traded $EW stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $EW stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 11/19.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Edwards Lifesciences Corporation Analyst Ratings
Wall Street analysts have issued reports on $EW in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/11/2026
- Piper Sandler issued a "Overweight" rating on 01/20/2026
- Stifel issued a "Buy" rating on 01/20/2026
- Barclays issued a "Overweight" rating on 01/12/2026
- TD Cowen issued a "Buy" rating on 01/09/2026
- Mizuho issued a "Outperform" rating on 10/31/2025
- RBC Capital issued a "Outperform" rating on 10/31/2025
To track analyst ratings and price targets for Edwards Lifesciences Corporation, check out Quiver Quantitative's $EW forecast page.
Edwards Lifesciences Corporation Price Targets
Multiple analysts have issued price targets for $EW recently. We have seen 17 analysts offer price targets for $EW in the last 6 months, with a median target of $98.0.
Here are some recent targets:
- Anthony Petrone from Mizuho set a target price of $95.0 on 04/13/2026
- Vijay Kumar from Evercore ISI Group set a target price of $92.0 on 04/06/2026
- Adam Maeder from Piper Sandler set a target price of $100.0 on 02/11/2026
- David Roman from Goldman Sachs set a target price of $95.0 on 02/11/2026
- Larry Biegelsen from Wells Fargo set a target price of $100.0 on 02/11/2026
- Richard Newitter from Truist Securities set a target price of $89.0 on 02/11/2026
- Marie Thibault from BTIG set a target price of $103.0 on 02/11/2026
